查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511925

個人化醫療市場規模、佔有率、趨勢分析報告：按產品、最終用途、地區、細分市場預測，2024-2030 年

Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

個人化醫療市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球個人化醫療市場規模將達到9,098億美元，2024年至2030年複合年成長率為8.20%。由於疾病發生率的增加和對新型療法的需求不斷增加，預計 2023 年至 2030 年該市場的複合年成長率將達到 7.20%。巨大的研究努力不斷增強個人化醫療的新興應用。例如，2022 年 7 月，麻省大學陳年醫學院的研究人員將使用基於微生物的個人化來幫助了解代謝變異，以測量個別基因組、飲食、微生物組和相關環境因素之間的關聯。

大多數癌症是由基因不匹配引起的，如果進展可能致命。了解特定的基因組特徵可以有效、精確地治療癌症。例如，2020 年 5 月，Qiagen 推出了 QIAseq 泛癌症多模式面板，旨在分析癌症受試者的基因組特徵，為固體癌和血紅素惡性的分析提供廣泛的精準醫學應用。

NGS 技術的進步和對人類基因組的廣泛研究積極推動了該市場。人們越來越有興趣利用 NGS 來獲得可用於治療癌症和罕見遺傳疾病的個人化醫療結果。例如，Illumina 宣布將在巴黎舉行的歐洲腫瘤學會 (ESMO) 年會上展示多項腫瘤學研究的摘要。 Illumina 的研究透過切片檢查的全面基因組分析將受試者與潛在的藥物和免疫療法相匹配，從而實現個人化癌症治療。

遠端醫療透過虛擬方式或透過電話提供臨床建議，以補充物理上的便利性。遠端醫療日益流行，特別是自 COVID-19 大流行以來。各國政府和研究機構正大力加強個人化遠端醫療的應用。例如，2022 年 8 月，美國國家癌症美國宣布提供 2,300 萬美元的五年津貼，支持在美國各地推出遠距醫療卓越遠端醫療中心 (TRACE)。

分子影像系統和醫療設備在個人化醫療的新進展中發揮著重要作用。分子影像系統和醫療設備正在有效地利用個人化醫療的應用來治療各種類型的癌症。例如，2022 年 6 月，GE Healthcare 宣布使用鎵 68 放射性同位素進行高階分子成像，用於前列腺癌診斷和監測。

由於新技術的進步以及聯盟和業務擴張等持續的行業努力，市場正處於成長階段。例如，2021 年 12 月，Biogen Inc. 和 TheraPanacea 宣佈建立合作關係，專注於推廣神經科學個人化醫療的數位健康。

個性化醫療市場報告亮點

  • 該市場的整體成長是由於對利用基因層面的疾病所了解的新型療法的不斷成長的需求以及全球癌症和遺傳疾病發病率的上升所推動的。
  • 由於藥物基因組學在生物製藥開發中的廣泛應用，個人化醫療治療領域預計將在預測期內實現高速成長。此外，由於全基因組定序成本大幅下降，預計基因組治療領域在預測期內將顯著成長。
  • 由於主要企業的存在以及對新療法開發的深入研究以尋找各種疾病的治療方法，北美將在 2023 年佔據市場主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章個人化醫療市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 個人化藥品市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章個人化醫療市場：產品評估與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的全球個人化醫療市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第5章個人化醫療市場：最終用途估計與趨勢分析

  • 2023年及2030年市場佔有率方法
  • 細分儀表板
  • 按最終用途分類的全球個人化醫療市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第6章個人化醫療市場：區域估算與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • GE Healthcare
    • Illumina, Inc.
    • ASURAGEN, INC.
    • Abbott
    • Dako A/S
    • Exact Sciences Corporation
    • Danaher Corporation（Cepheid, Inc.）
    • Decode Genetics, Inc.
    • QIAGEN
    • Exagen Inc.
    • Precision Biologics
    • Celera Diagnostics LLC
    • Biogen
    • Genelex
    • IBM
    • Genentech, Inc.
    • 23andMe, Inc.
Product Code: 978-1-68038-443-7

Personalized Medicine Market Growth & Trends:

The global personalized medicine market size is expected to reach USD 909.80 billion by 2030, expanding at a CAGR of 8.20% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 7.20% from 2023 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Personalized Medicine Market Report Highlights:

  • The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe
  • The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing
  • North America dominated the market in 2023 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Personalized Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in next-generation sequencing technology
      • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
      • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for personalized medicine cancer therapy
      • 3.2.1.4. Technological advancements to facilitate R&D for personalized medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of nonvalue-based personalized medicine diagnostics reimbursement policy
      • 3.2.2.2. Lack of proper intellectual property regulations for personalized medical technologies
  • 3.3. Personalized Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Personalized Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Personalized Medicine Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Personalized Medicine Diagnostics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.2. Genetic Testing
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.3. DTC Diagnostics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.4. Esoteric Lab Services
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.5. Esoteric Lab Tests
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Personalized Medicine Therapeutics
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.2. Pharmaceutical
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.3. Genomic Medicine
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.4. Medical Devices
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Personalized Medical Care
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.2. Telemedicine
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.3. Health Information Technology
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Personalized Nutrition & Wellness
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.4.2. Retail Nutrition
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.4.3. Complementary & Alternative Medicine
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Personalized Medicine Market: End-use Estimates & Trend Analysis

  • 5.1. Method Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Personalized Medicine Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Academic & Research Institutes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Diagnostic Centers
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. GE Healthcare
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Illumina, Inc.
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. ASURAGEN, INC.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Abbott
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Dako A/S
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Exact Sciences Corporation
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Danaher Corporation (Cepheid, Inc.)
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. Decode Genetics, Inc.
      • 7.3.11.1. Overview
      • 7.3.11.2. Financial Performance
      • 7.3.11.3. Product Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. QIAGEN
      • 7.3.12.1. Overview
      • 7.3.12.2. Financial Performance
      • 7.3.12.3. Product Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Exagen Inc.
      • 7.3.13.1. Overview
      • 7.3.13.2. Financial Performance
      • 7.3.13.3. Product Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. Precision Biologics
      • 7.3.14.1. Overview
      • 7.3.14.2. Financial Performance
      • 7.3.14.3. Product Benchmarking
      • 7.3.14.4. Strategic Initiatives
    • 7.3.15. Celera Diagnostics LLC
      • 7.3.15.1. Overview
      • 7.3.15.2. Financial Performance
      • 7.3.15.3. Product Benchmarking
      • 7.3.15.4. Strategic Initiatives
    • 7.3.16. Biogen
      • 7.3.16.1. Overview
      • 7.3.16.2. Financial Performance
      • 7.3.16.3. Product Benchmarking
      • 7.3.16.4. Strategic Initiatives
    • 7.3.17. Genelex
      • 7.3.17.1. Overview
      • 7.3.17.2. Financial Performance
      • 7.3.17.3. Product Benchmarking
      • 7.3.17.4. Strategic Initiatives
    • 7.3.18. IBM
      • 7.3.18.1. Overview
      • 7.3.18.2. Financial Performance
      • 7.3.18.3. Product Benchmarking
      • 7.3.18.4. Strategic Initiatives
    • 7.3.19. Genentech, Inc.
      • 7.3.19.1. Overview
      • 7.3.19.2. Financial Performance
      • 7.3.19.3. Product Benchmarking
      • 7.3.19.4. Strategic Initiatives
    • 7.3.20. 23andMe, Inc.
      • 7.3.20.1. Overview
      • 7.3.20.2. Financial Performance
      • 7.3.20.3. Product Benchmarking
      • 7.3.20.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 3 North America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 4 North America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 7 Canada Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 8 Canada Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 9 Europe Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 11 Europe Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 12 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 13 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 14 Germany Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 15 Germany Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 16 UK Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 17 UK Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 18 Spain Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 19 Spain Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 20 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 21 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 22 Italy Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 23 Italy Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 24 Sweden Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 25 Sweden Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 26 Norway Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 27 Norway Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 28 Denmark Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 29 Denmark Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 31 Asia Pacific Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 32 Asia Pacific Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 33 Japan Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 34 Japan Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 35 China Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 36 China Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 37 India Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 38 India Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 41 Australia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 42 Australia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 43 Thailand Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 44 Thailand Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 45 Latin America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 46 Latin America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 47 Latin America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 48 Brazil Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 49 Brazil Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 50 Mexico Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 51 Mexico Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 52 Argentina Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 53 Argentina Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
  • Table 54 MEA Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 55 MEA Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 MEA Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 57 South Africa Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 58 South Africa Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 61 UAE Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 62 UAE Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Personalized medicine market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global personalized medicine market, for product, 2018 - 2030 (USD Billion)
  • Fig. 15 Global personalized medicine market, for diagnostics, 2018 - 2030 (USD Billion)
  • Fig. 16 Global personalized medicine market, for genetic testing, 2018 - 2030 (USD Billion)
  • Fig. 17 Global personalized medicine market, for direct-to-consumer (DTC) testing, 2018 - 2030 (USD Billion)
  • Fig. 18 Global personalized medicine market, for esoteric lab services, 2018 - 2030 (USD Billion)
  • Fig. 19 Global personalized medicine market, for esoteric lab tests, 2018 - 2030 (USD Billion)
  • Fig. 20 Global personalized medicine market, for therapeutics, 2018 - 2030 (USD Billion)
  • Fig. 21 Global personalized medicine market, for pharmaceutical, 2018 - 2030 (USD Billion)
  • Fig. 22 Global personalized medicine market, for genomic medicine, 2018 - 2030 (USD Billion)
  • Fig. 23 Global personalized medicine market, for medical devices, 2018 - 2030 (USD Billion)
  • Fig. 24 Global personalized medicine market, for personalized medical care, 2018 - 2030 (USD Billion)
  • Fig. 25 Global personalized medicine market, for telemedicine, 2018 - 2030 (USD Billion)
  • Fig. 26 Global personalized medicine market, for health information technology, 2018 - 2030 (USD Billion)
  • Fig. 27 Global personalized medicine market, for personalized nutrition & wellness, 2018 - 2030 (USD Billion)
  • Fig. 28 Global personalized medicine market, for retail nutrition, 2018 - 2030 (USD Billion)
  • Fig. 29 Global personalized medicine market, for complementary & alternative medicine, 2018 - 2030 (USD Billion)
  • Fig. 30 Global personalized medicine market, for End-use, 2018 - 2030 (USD Billion)
  • Fig. 31 Global personalized medicine market, for diagnostics centers, 2018 - 2030 (USD Billion)
  • Fig. 32 Global personalized medicine market, for academic and research institutes, 2018 - 2030 (USD Billion)
  • Fig. 33 Global personalized medicine market, for hospitals, 2018 - 2030 (USD Billion)
  • Fig. 34 Global personalized medicine market, for others, 2018 - 2030 (USD Billion)
  • Fig. 35 Regional outlook, 2023 & 2030
  • Fig. 36 North America personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 37 U.S. personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 38 Canada personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 39 Europe personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 40 Germany personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 41 UK personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 42 France personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 43 Italy personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 44 Spain personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 45 Denmark personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 46 Sweden personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 48 Asia Pacific personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 49 Japan personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 50 China personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 51 India personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 52 Australia personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 53 Thailand personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 54 South Korea personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 55 Latin America personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 56 Brazil personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 57 Mexico personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 58 Argentina personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 59 MEA personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 60 South Africa personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 61 Saudi Arabia personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 62 UAE personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 63 Kuwait personalized medicine market, 2018 - 2030 (USD Billion)